nach oben

Current Hypertension Reports

Erschienen in:

01.04.2011

The Role of Aldosterone in the Metabolic Syndrome

verfasst von: Marie Briet, Ernesto L. Schiffrin

Erschienen in: Current Hypertension Reports | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

The metabolic syndrome associates metabolic abnormalities such as insulin resistance and dyslipidemia with increased waist circumference and hypertension. It is a major public health concern, as its prevalence could soon reach 30% to 50% in developed countries. Aldosterone, a mineralocorticoid hormone classically involved in sodium balance regulation, is increased in patients with metabolic syndrome. Besides its classic actions, aldosterone and mineralocorticoid receptor (MR) activation affect glucose metabolism, inducing insulin resistance through various mechanisms that involve oxidative stress, inflammation, and downregulation of proteins involved in insulin signaling pathways. Aldosterone and MR signaling exert deleterious effects on the cardiovascular system and the kidney that influence the cardiovascular risk associated with metabolic syndrome. Salt load plays a major role in cardiovascular injury induced by aldosterone and MR signaling. Large multicenter, randomized clinical trials testing the beneficial effects of MR antagonists on cardiovascular events and mortality in patients with metabolic syndrome are needed.

Eckel RH, Alberti KG, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2010, 375:181–183.PubMedCrossRef

•• Alberti KG, Eckel RH, Grundy SM, et al.: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640–1645. This paper is of particular interest, as it describes the new diagnostic criteria for the metabolic syndrome. PubMedCrossRef

Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709–2716.PubMedCrossRef

• Motillo S, Filion KB, Genest J, et al.: The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol 2010, 56:1113–1132. This recent meta-analysis described the high cardiovascular risk associated with the metabolic syndrome, using the definition of the National Cholesterol Education Program.CrossRef

Briet M, Schiffrin EL: Aldosterone: effects on the kidney and cardiovascular system. Nat.Rev.Nephrol. 2010, 6:261–273.PubMedCrossRef

Ingelsson E, Pencina MJ, Tofler GH, et al.: Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 2007, 116:984–992.PubMedCrossRef

Chartier L, Schiffrin E, Thibault G, et al.: Atrial natriuretic factor inhibits the stimulation of aldosterone secretion by angiotensin II, ACTH and potassium in vitro and angiotensin II-induced steroidogenesis in vivo. Endocrinology 1984, 115:2026–2028.PubMedCrossRef

• Urbanet R, Pilon C, Calcagno A, et al.: Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism. J Clin Endocrinol Metab 2010, 95:4037–4042. This study is the first one to test insulin sensitivity in adipose tissue obtained from patients with primary aldosteronism and controls. The authors did not demonstrate insulin resistance in vitro after aldosterone administration in primary adipocyte cell culture. PubMedCrossRef

•• Funder JW: Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009, 53:286–290. This review raises the important question of the role of glucocorticoids acting through MR activation.

10.

Edwards CR, Stewart PM, Burt D, et al.: Localisation of 11 beta-hydroxysteroid dehydrogenase—tissue specific protector of the mineralocorticoid receptor. Lancet 1988, 2:986–989.PubMedCrossRef

11.

Veilleux A, Laberge PY, Morency J, et al.: Expression of genes related to glucocorticoid action in human subcutaneous and omental adipose tissue. J Steroid Biochem Mol Biol 2010, 122:28–34.PubMedCrossRef

12.

Funder J, Myles K: Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 1996, 137:5264–5268.PubMedCrossRef

13.

Funder JW, Reincke M: Aldosterone: a cardiovascular risk factor? Biochim Biophys Acta 2010, 1802:1188–1192.PubMed

14.

Tuck ML, Sowers J, Dornfeld L, et al.: The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981, 304:930–933.PubMedCrossRef

15.

Rossi GP, Belfiore A, Bernini G, et al.: Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008, 93:2566–2571.PubMedCrossRef

16.

Bentley-Lewis R, Adler GK, Perlstein T, et al.: Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 2007, 92:4472–4475.PubMedCrossRef

17.

Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ: Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 1999, 7:355–362.PubMed

18.

Engeli S, Bohnke J, Gorzelniak K, et al.: Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005, 45:356–362.PubMedCrossRef

19.

Gorzelniak K, Engeli S, Janke J, et al.: Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 2002, 20:965–973.PubMedCrossRef

20.

Petrasek D, Jensen G, Tuck M, Stern N: In vitro effects of insulin on aldosterone production in rat zona glomerulosa cells. Life Sci 1992, 50:1781–1787.PubMedCrossRef

21.

Colussi G, Catena C, Lapenna R, et al.: Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007, 30:2349–2354.PubMedCrossRef

22.

Goodfriend TL, Egan B, Stepniakowski K, Ball DL: Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension 1995, 25:30–36.PubMed

23.

• Jeon JH, Kim KY, Kim JH, et al.: A novel adipokine CTRP1 stimulates aldosterone production. FASEB J 2008, 22:1502–1511. This paper provides one of the explanations for the link between obesity and aldosterone synthesis. The authors demonstrated that C1q TNF-related protein (CTRP)1, an adipokine, stimulates the synthesis of aldosterone by cells from the human adrenal cortical cell line H295R. PubMedCrossRef

24.

Goodfriend TL, Ball DL, Raff H, et al.: Oxidized products of linoleic acid stimulate adrenal steroidogenesis. Endocr Res 2002, 28:325–330.PubMedCrossRef

25.

Goodfriend TL, Ball DL, Egan BM, et al.: Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004, 43:358–363.PubMedCrossRef

26.

Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al.: Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003, 100:14211–14216.PubMedCrossRef

27.

Devenport LD, Goodwin KG, Hopkins PM: Continuous infusion of aldosterone: correlates of body weight gain. Pharmacol Biochem Behav 1985, 22:707–709.PubMedCrossRef

28.

Caprio M, Feve B, Claes A, et al.: Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007, 21:2185–2194.PubMedCrossRef

29.

Berg AH, Scherer PE: Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005, 96:939–949.PubMedCrossRef

30.

Abbasi A, Corpeleijn E, Postmus D, et al.: Plasma procalcitonin is associated with obesity, insulin resistance, and the metabolic syndrome. J Clin Endocrinol Metab 2010, 95:E26–E31.PubMedCrossRef

31.

Guo C, Ricchiuti V, Lian BQ, et al.: Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008, 117:2253–2261.PubMedCrossRef

32.

Hirata A, Maeda N, Hiuge A, et al.: Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009, 84:164–172.PubMedCrossRef

33.

Takebayashi K, Matsumoto S, Aso Y, Inukai T: Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006, 91:2214–2217.PubMedCrossRef

34.

• Savoia C, Touyz RM, Amiri F, Schiffrin EL: Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008, 51:432–439. This clinical study involving hypertensive patients demonstrated the beneficial effect of eplerenone, an MR blocker, on inflammation and resistance artery stiffness. PubMedCrossRef

35.

Conn JW: Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 1965, 273:1135–1143.PubMedCrossRef

36.

Fallo F, Veglio F, Bertello C, et al.: Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006, 91:454–459.PubMedCrossRef

37.

Catena C, Lapenna R, Baroselli S, et al.: Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006, 91:3457–3463.PubMedCrossRef

38.

Freel EM, Tsorlalis IK, Lewsey JD, et al.: Aldosterone status associated with insulin resistance in patients with heart failure—data from the ALOFT study. Heart 2009, 95:1920–1924.PubMedCrossRef

39.

Garg R, Hurwitz S, Williams GH, et al.: Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab 2010, 95:1986–1990.PubMedCrossRef

40.

Ranade K, Wu KD, Risch N, et al.: Genetic variation in aldosterone synthase predicts plasma glucose levels. Proc Natl Acad Sci U S A 2001, 98:13219–13224.PubMedCrossRef

41.

Kraus D, Jager J, Meier B, et al.: Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res 2005, 37:455–459.PubMedCrossRef

42.

Lastra G, Whaley-Connell A, Manrique C, et al.: Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008, 295:E110–E116.PubMedCrossRef

43.

Wada T, Ohshima S, Fujisawa E, et al.: Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3 T3-L1 adipocytes. Endocrinology 2009, 150:1662–1669.PubMedCrossRef

44.

Hitomi H, Kiyomoto H, Nishiyama A, et al.: Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007, 50:750–755.PubMedCrossRef

45.

Yamashita R, Kikuchi T, Mori Y, et al.: Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. Endocr J 2004, 51:243–251.PubMedCrossRef

46.

• Wada T, Kenmochi H, Miyashita Y, et al.: Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 2010, 151:2040–2049. The authors demonstrated the role of MR activation in hepatic steatosis, inflammation, and oxidative stress in mice receiving a high-fat and high-fructose diet. They also demonstrated that MR activation is implicated in hepatic gluconeogenesis, which could participate in the impairment of glucose metabolism associated with metabolic syndrome. PubMedCrossRef

47.

Bochud M, Nussberger J, Bovet P, et al.: Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006, 48:239–245.PubMedCrossRef

48.

Kathiresan S, Larson MG, Benjamin EJ, et al.: Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am J Hypertens 2005, 18:657–665.PubMedCrossRef

49.

Joffe HV, Kwong RY, Gerhard-Herman MD, et al.: Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007, 92:2552–2558.PubMedCrossRef

50.

Matsumoto S, Takebayashi K, Aso Y: The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 2006, 55:1645–1652.PubMedCrossRef

51.

Matsui H, Ando K, Kawarazaki H, et al.: Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension 2008, 52:287–294.PubMedCrossRef

52.

Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321.PubMedCrossRef

53.

Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717.PubMedCrossRef

54.

Young M, Fullerton M, Dilley R, Funder J: Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994, 93:2578–2583.PubMedCrossRef

55.

Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992, 120:893–901.PubMed

56.

Nakano S, Kobayashi N, Yoshida K, et al.: Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens Res 2005, 28:925–936.PubMedCrossRef

57.

Endemann DH, Touyz RM, Iglarz M, et al.: Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2004, 43:1252–1257.PubMedCrossRef

58.

Somers MJ, Mavromatis K, Galis ZS, Harrison DG: Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 2000, 101:1722–1728.PubMed

59.

Beswick RA, Zhang H, Marable D, et al.: Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 2001, 37:781–786.PubMed

60.

Sun Y, Zhang J, Lu L, et al.: Aldosterone-induced inflammation in the rat heart : role of oxidative stress. Am J Pathol 2002, 161:1773–1781.PubMedCrossRef

61.

Ammarguellat F, Larouche I, Schiffrin EL: Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism. Circulation 2001, 103:319–324.PubMed

62.

Park JB, Schiffrin EL: Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens 2002, 15:164–169.PubMedCrossRef

63.

Pu Q, Neves MF, Virdis A, et al.: Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003, 42:49–55.PubMedCrossRef

64.

Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996, 98:1063–1068.PubMedCrossRef

65.

Nishiyama A, Yao L, Nagai Y, et al.: Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004, 43:841–848.PubMedCrossRef

66.

Shibata S, Nagase M, Yoshida S, et al.: Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007, 49:355–364.PubMedCrossRef

67.

Nagase M, Yoshida S, Shibata S, et al.: Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J.Am.Soc.Nephrol. 2006, 17:3438–3446.

68.

Gross ML, Ritz E, Schoof A, et al.: Comparison of renal morphology in the Streptozotocin and the SHR/N-cp models of diabetes. Lab Invest 2004, 84:452–464.PubMedCrossRef

69.

Nagase M, Matsui H, Shibata S, et al.: Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007, 50:877–883.PubMedCrossRef

Titel: The Role of Aldosterone in the Metabolic Syndrome
verfasst von: Marie Briet
Ernesto L. Schiffrin
Publikationsdatum: 01.04.2011
Verlag: Current Science Inc.
Erschienen in: Current Hypertension Reports / Ausgabe 2/2011
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-011-0182-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir nicht substanzbedingt Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Knocking Out Angiotensin II in the Heart

Estimation of Glomerular Filtration Rate: What Are the Pitfalls?

Nycthemeral Relationship between Renal Function and Sodium Homeostasis

Metabolic Syndrome, Androgens, and Hypertension

Metabolic Syndrome and Heart Failure—The Risk, Paradox, and Treatment